Takeda To Take Dengue Vaccine Into Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical plans to begin Phase III trials the next fiscal year for its dengue-fever vaccine with expectations of launching it in Europe and the U.S. within FY 2017-18.